Legend Biotech Corporation
NASDAQ:LEGNBiotechnology
-$4.53 today
- Market cap
- $3.01B
- Beta
- 0.35
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.35
Volume 2.15M
Average 2.42M
LEGN Total Current Liabilities
All obligations due within one year.
Legend Biotech CorporationNASDAQ: LEGN
Total Current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total current liabilities falls 33.2% from a year ago
Total current liabilities stood at $289.6M at the end of Q3 FY2026, down 33.2% from a year earlier and down 28.2% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Total current liabilities amounted to 17.2% of total assets at the end of Q3 FY2026, down 8.1 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -33.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 636.4M USD
- Year-over-year change
- +129.2%
- 4-year CAGR
- +29.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 636.4M | +129.2% |
| FY2024 | 2024-12-31 | 277.65M | +28.3% |
| FY2023 | 2023-12-31 | 216.42M | -27.3% |
| FY2022 | 2022-12-31 | 297.79M | +29.9% |
| FY2021 | 2021-12-31 | 229.2M | — |
Total Current Liabilities vs competitors
How LEGN compares with its peers on the latest reported figures
- LEGN's Sep 2026 total current liabilities of $289.6M is the highest of the 11 companies compared; the peer median is $24M.
- Its year-over-year change of -33.2% is the 9th highest of 11, against a peer median of -8.5%.
- Total current liabilities amounts to 17.2% of total assets for LEGN, versus a peer median of 10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $289.6M | -33.2% | +28.8% | 17.2% | |
| Mar 2026 | $134.5M | -17.3% | +32.3% | 46.5% | |
| Mar 2026 | $63.6M | -4.5% | +16.6% | 12.1% | |
| Mar 2026 | $36.95M | -10.5% | +10.1% | 10.5% | |
| Mar 2026 | $30.69M | +9.0% | -31.9% | 10.8% | |
| Mar 2026 | $28.33M | -5.6% | -15.4% | 7.2% | |
| Mar 2026 | $19.67M | -31.0% | -3.3% | 13.2% | |
| Mar 2026 | $15.95M | +6.3% | -15.9% | 5.5% | |
| Mar 2026 | $13.57M | -6.5% | -12.1% | 4.2% | |
| Mar 2026 | $7.76M | -37.4% | -46.9% | 5.4% | |
| Mar 2026 | $5.65M | -88.2% | -42.6% | 28.2% | |
| Peer median (excluding LEGN) | $24M | -8.5% | -13.8% | 10.7% | |
Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 688.94M | 786.03M | 1.28B | 286.75M | 901.9M |
| Short-term Investments | 193.46M | 239.62M | 31M | 835.93M | 46.7M |
| Net Receivables | 58.55M | 44.52M | 157.06M | 124.89M | 250.3M |
| Inventory | 1.75M | 10.35M | 19.43M | 23.9M | 32M |
| Other Current Assets | 1.44M | 1.27M | 357K | 70K | 1.6M |
| Total Current Assets | 949.85M | 1.1B | 1.5B | 1.28B | 1.25B |
| Property, Plant & Equipment (Net) | 142.96M | 161.67M | 189.68M | 201.59M | 402M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 16.81M | 68.69M | 4.06M | 174.22M | 74.6M |
| Long-term Investments | 4.71M | 0 | 4.36M | 4.36M | 5M |
| Tax Assets | 0 | 0 | 285K | 0 | 0 |
| Other Non-current Assets | 5.15M | 1.49M | 152.42M | 6.06M | 5M |
| Total Non-current Assets | 169.62M | 231.84M | 350.81M | 386.24M | 486.6M |
| Total Assets | 1.12B | 1.33B | 1.85B | 1.67B | 1.73B |
| Account Payables | 7.04M | 31.69M | 20.16M | 37.19M | 81.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 319.1M |
| Tax Payables | 10M | 10.79M | 7.2M | 24.04M | 0 |
| Deferred Revenue | 304K | 451K | 53.01M | 47.41M | 11.3M |
| Other Current Liabilities | 87.9M | 67M | 68K | 500K | 1M |
| Total Current Liabilities | 229.2M | 297.79M | 216.42M | 277.65M | 636.4M |
| Long-term Debt | 120.46M | 260.93M | 281.33M | 301.2M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.87M | 7.66M | 55.27M | 6.15M | 0 |
| Other Non-current Liabilities | 396K | 233K | 56K | (54K) | 8M |
| Total Non-current Liabilities | 124.32M | 288.86M | 380.82M | 351.96M | 95.2M |
| Total Liabilities | 353.52M | 586.65M | 597.24M | 629.61M | 731.6M |
| Common Stock | 31K | 33K | 36K | 37K | 100K |
| Retained Earnings | (520.11M) | (966.46M) | (1.48B) | (1.66B) | (1.96B) |
| Accumulated OCI | 4.86M | 14.67M | 98.93M | (68.16M) | 122.2M |
| Other Stockholders Equity | 19.7M | 39.05M | 0 | 74.43M | 88M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 765.94M | 744.31M | 1.25B | 1.04B | 1B |
| Total Debt | 122.97M | 284.53M | 328.67M | 350.6M | 413.7M |
| Net Debt | (565.97M) | (501.5M) | (949.04M) | 63.85M | (488.2M) |
Legend Biotech Corporation
NASDAQ:LEGN
Intrinsic Alpha fair value
Locked
Current Price
$16.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.